QURE Biotechnology · Gene therapy · Clinical stage · Rare disease · Thesis updated August 11, 2026

A U.S. pathway reopens, shifting the regulatory story

The FDA agreed an accelerated approval submission for AMT-130 is reasonable for Q3 2026.
The agency dropped its sham surgery mandate, asking for a standard-of-care confirmatory trial instead.
A capital raise of $242.7 million extends the cash runway into 2030.
AMT-260 showed 79 to 100 percent seizure reductions in half of low-dose patients.
The company plans to submit a U.K. application in Q3 2026, creating a dual regulatory track.

01 Running thesis

One asset, two regulators, renewed hope

The story completely flipped in Q2 2026. After previously demanding a new sham-controlled trial for the Huntington's disease drug AMT-130, the FDA reversed course. It now agrees that submitting a Biologics License Application for accelerated approval using existing data is reasonable.

uniQure expects to file that U.S. application, along with a U.K. equivalent, in Q3 2026. This dual-track filing plan restores the near-term catalyst that investors thought was lost. A massive June 2026 capital raise also extended the cash runway into 2030, giving the company years of flexibility.

The bull case is clear. The U.S. accelerated approval pathway is back open, and the company has the cash to follow it. Furthermore, the pipeline is showing early life, with the AMT-260 epilepsy program demonstrating meaningful seizure reductions in its lowest dose cohort.

The bear case centers on the regulatory finish line. Submitting an application does not guarantee approval. The FDA still requires a standard-of-care confirmatory trial to be well underway by the time of any accelerated approval. Enrolling patients in that trial could be slow, and the AMT-191 safety pause shows that early-stage pipeline risks remain high.

Jul 2026▲The FDA reversed its prior stance, agreeing an accelerated approval submission for AMT-130 is reasonable based on existing data. A June follow-on offering raised $242.7 million, extending the cash runway into 2030.

May 2026▲uniQure added a major new catalyst by planning a U.K. AMT-130 filing in Q3 2026 after MHRA feedback. It also extended cash runway guidance into the second half of 2029, but the future U.S. trial cost remains an open issue.

May 2026▼The company formally discontinued AMT-162 for ALS. That narrows the pipeline and makes AMT-130 even more important.

Mar 2026▼The FDA's position on AMT-130 became clear. It does not view the Phase I/II data with an external control as enough main proof for a U.S. marketing application and strongly recommended a new sham-controlled study.

Mar 2026→Management planned a Q2 2026 Type B meeting with the FDA to discuss the U.S. pivotal trial design. This gave investors a next step, but not yet a cost or timeline.

Nov 2025▼The earlier plan for a near-term U.S. BLA filing broke after the FDA no longer appeared to support the external control pathway. Positive 3-year data could not remove the regulatory overhang.

Nov 2025▲uniQure reported positive 3-year AMT-130 data and a much larger cash balance after financing. That supported the science case, even as the U.S. regulatory path worsened.

Jul 2025▲The company had previously reported FDA alignment on the AMT-130 statistical analysis plan and CMC path for a planned BLA. That was the old bull case before the later FDA reversal.

02 Business model

Royalties fund a trial story

uniQure develops one-time gene therapies for serious rare diseases. These treatments try to fix or change disease biology with a single administration, rather than requiring chronic dosing.

The only approved product tied to uniQure is HEMGENIX for Hemophilia B. CSL Behring commercializes it, and uniQure receives royalties and milestone payments. In early 2026, license revenue made up the entire revenue base.

The company previously subcontracted its manufacturing of HEMGENIX to Genezen. In April 2026, uniQure agreed to terminate this commercial supply agreement, ending its supply obligation once specified batches are delivered. The company relies on outsourced manufacturing for its clinical-stage pipeline.

The core value driver is the clinical and regulatory success of its pipeline. The business relies on external capital raises, like the June 2026 offering, to fund costly trials until those candidates can be commercialized or licensed.

03 Product portfolio

What uniQure is betting on

Growth engine

AMT-130

The lead program for Huntington's disease. The company plans to submit both a U.S. BLA and a U.K. MAA in Q3 2026.

Cash cow

HEMGENIX

An approved gene therapy for Hemophilia B sold by CSL Behring. It provides royalty revenue but is not the primary driver of the stock.

Option

AMT-260

A clinical candidate for refractory mesial temporal lobe epilepsy. Early data showed meaningful seizure reductions for a subset of low-dose patients.

Option

AMT-191

A clinical candidate for Fabry disease. Dosing in mid- and high-dose cohorts remains paused pending evaluation of dose-limiting toxicities.

04 Business segments

Revenue is one stream today

License revenues100%flat

Contract manufacturing revenues0%declining

Collaboration revenues0%flat

For Q2 2026, uniQure reported revenue primarily from licenses. The company operates as a single business segment focused on gene therapy development.

05 Risk factors

What could break the story

Confirmatory trial requirements

High impact · High odds

The FDA agreed a BLA submission is reasonable, but it requires a standard-of-care confirmatory trial to be well underway before potential approval. Exact enrollment and powering requirements are still unknown.

We watchFDA alignment on the confirmatory study design for AMT-130.

BLA and MAA review timelines

High impact · Medium odds

Submissions are planned for Q3 2026, but regulators could refuse to file them or issue a complete response letter. A rejection would severely damage the stock.

We watchFDA and MHRA acceptance of the applications and potential PDUFA date assignments.

Pipeline safety setbacks

Medium impact · Medium odds

Dosing in the AMT-191 trial for Fabry disease is paused due to dose-limiting toxicities. Early-stage development risk remains high across the broader portfolio.

We watchUpdates on the AMT-191 clinical hold and whether dosing resumes.

Clinical enrollment delays

Medium impact · Low odds

The newly required standard-of-care trial for AMT-130 could face enrollment challenges. If the trial is not well underway, the FDA may delay final approval.

We watchPatient recruitment updates for the AMT-130 confirmatory trial.

06 Quick answers

In one breath

What is the status of AMT-130?

The FDA agreed that a U.S. Biologics License Application for accelerated approval is reasonable for Q3 2026. The company also plans to file in the U.K. at the same time.

How is uniQure funded?

A June 2026 equity offering raised $242.7 million, extending the cash runway into 2030. The company also earns royalties on HEMGENIX.

What happened to the manufacturing business?

uniQure terminated its commercial supply agreement with Genezen in April 2026. It is moving away from supplying HEMGENIX after final batches are delivered.